

PHARMACY MANUFACTURING UNIT/QUALITY CONTROL Section: Materials and Containers	Doc Ref: F358a
	Issue: 5
Subject: Artwork Design Approval Sheet	Owner: K Connor
	Ref: P358

Product:
Ivermectin (3 mg) tablets – U9208P

Ivermectin 3mg tablets	
The capsules are for oral administration. Dosage is dependent on body weight - 45-64 kg: Take a single dose of 18mg (6 tablets) each day for three days (18 tablets in total) 65-84 kg: Take a single dose of 24 mg (8 tablets) each day for three days (24 tablets in total) ≥84 kg: Take a single dose of 30mg (10 tablets) each day for 3 days (30 tablets in total). Please return any remaining tablets to the trial team. Special instructions: You should take the daily number of tablets in one dose. The dose may be taken at any time of the day, but no food should be taken within two hours before or after administration. Batch Number: V Expiry: Vvvvvvvvvvv	Trial subject identification number: Kit/Pack number: For clinical trial use only Keep out of the sight and reach of children. Store below 30°C Period of Use: 3 days PRINCIPLE trial. University of Oxford. Chief Investigator: Prof. Chris Butler University of Oxford Joint Research Office , 1st floor, Boundary Brook House , Churchill Drive, Headington ,Oxford OX3 7GB Tel: +44 (0)1865572224 Fax: +44 (0)1865572228 9208PAD1



12 Cartons

Ivermectin 3mg tablets

Clinical Trial

BN 00000000 EXP 01/2001



Store below 30°C

Design
 9208PC01

Label (/box/case) :

Code: **U9208P**

Draft Number: 4

Amendments/Changes: New labels created. Please be aware that batch data is to show format. Additional field for 'investigator' removed.

Designed/Issued:	Kyle Connor	(Artwork Team TP)	Date:	26.05.2021
Approved:	<u>Hannah Swayze</u> Hannah Swayze (May 26, 2021 10:09 GMT+1)	(Customer)	Date:	May 26, 2021
Approved:	<u>E. Ogburn</u> E. Ogburn (May 26, 2021 18:36 GMT+1)	(Customer QA/QC)	Date:	May 26, 2021
Approved:	<u>Julie Adams</u>	(Quality TP)	Date:	May 26, 2021

F358a Ivermectin ver4

Final Audit Report

2021-05-26

Created:	2021-05-26
By:	Kyle Connor (kyleconnor@nhs.net)
Status:	Signed
Transaction ID:	CBJCHBCAABAAu5m51ryG5hMsrq1itCGWwh7kqB2A1NUh

"F358a Ivermectin ver4" History

-  Document created by Kyle Connor (kyleconnor@nhs.net)
2021-05-26 - 08:35:21 GMT - IP address: 208.127.198.22
-  Document emailed to Sally Andrews (sally.andrews@nhs.net) for signature
2021-05-26 - 08:38:26 GMT
-  Email viewed by Sally Andrews (sally.andrews@nhs.net)
2021-05-26 - 08:39:35 GMT - IP address: 208.127.198.220
-  Document e-signed by Sally Andrews (sally.andrews@nhs.net)
Signature Date: 2021-05-26 - 08:40:34 GMT - Time Source: server- IP address: 208.127.198.220
-  Document emailed to Hannah Swayze (hannah.swayze@phc.ox.ac.uk) for signature
2021-05-26 - 08:40:36 GMT
-  Email viewed by Hannah Swayze (hannah.swayze@phc.ox.ac.uk)
2021-05-26 - 08:41:49 GMT - IP address: 129.67.119.128
-  Document e-signed by Hannah Swayze (hannah.swayze@phc.ox.ac.uk)
Signature Date: 2021-05-26 - 09:06:39 GMT - Time Source: server- IP address: 129.67.119.128
-  Document emailed to E.Ogburn (emma.ogburn@phc.ox.ac.uk) for signature
2021-05-26 - 09:06:41 GMT
-  Email viewed by E.Ogburn (emma.ogburn@phc.ox.ac.uk)
2021-05-26 - 17:35:05 GMT - IP address: 90.221.192.136
-  Document e-signed by E.Ogburn (emma.ogburn@phc.ox.ac.uk)
Signature Date: 2021-05-26 - 17:36:01 GMT - Time Source: server- IP address: 90.221.192.136
-  Agreement completed.
2021-05-26 - 17:36:01 GMT